Business
Collaboration with Pre Diagnostics AS
Collaboration with Pre Diagnostics AS.
About this update from Bioventix Plc
[{"type":"text","content":"\n \n\n\n\n \n\n\n\nPress release\n\nBioventix plc\n\n(“Bioventix†or the “Companyâ€)\n\nPre Diagnostics and Bioventix enter collaboration on blood-based beta amyloid Alzheimer’s diagnostic test\n\nOslo, 31 May 2016, Norwegian Alzheimer’s diagnostics company Pre Diagnostics AS today announced a collaboration with leading UK antibody specialist Bioventix plc (BVXP). Under the terms of the agreement Bioventix will develop and provide antibodies for Pre Diagnostics new patient-friendly IVD test for dementia based on mid domain beta amyloid detection.\n\nThe inventor of Pre Diagnostics’ approach, Professor Tormod Fladby of Akershus University Hospital and the University of Oslo commented on the clinical need: “Alzheimer's disease develops over many years and the brain adapts to the disease. It can take 10-20 years before dementia onset. By then is it too late to reverse the disease symptoms and brain degeneration. Early detection of disease activity is likely to allow more effective treatment early in the disease course, and may improve quality of life and delay disease progression for patients with Alzheimer's disease. Our research, on which the new test is based, shows that Alzheimer’s disease is accompanied by systemic responses in certain white blood cells (macrophages) unique to the disease which can be accurately measured in the blood samples of patients.â€\n\nPre Diagnostics CEO HÃ¥kon Sæterøy commented. “By working with Bioventix, utilising their in-depth antibody and ELISA expertise, we aim to further optimise our current prototype blood-based Alzheimer’s test which has already shown promise in preliminary testingâ€. \n\nAccording to Sæterøy, the company is now on track for launching a research only test in 2017: “It is now widely accepted that a new blood-based test with high accuracy in the early disease stages is essential to accelerate effective drug development and intervention within the Alzheimer’s space. We aim to develop such tests that effectively demonstrate any intervention effect on the key disease mechanisms.â€\n\nPeter Harrison, CEO of Bioventix plc said: “We are delighted to be involved with Pre Diagnostics and their beta amyloid project. We are very impressed by the Oslo-based group and their research partners,...